Literature DB >> 21087604

Paracrine regulation of growth factor signaling by shed leucine-rich repeats and immunoglobulin-like domains 1.

Wei Yi1, Camilla Holmlund, Jonas Nilsson, Shigeki Inui, Ting Lei, Satoshi Itami, Roger Henriksson, Håkan Hedman.   

Abstract

Leucine-rich repeats and immunoglobulin-like domains 1 (LRIG1) is a recently discovered negative regulator of growth factor signaling. The LRIG1 integral membrane protein has been demonstrated to regulate various oncogenic receptor tyrosine kinases, including epidermal growth factor (EGF) receptor (EGFR), by cell-autonomous mechanisms. Here, we investigated whether LRIG1 ectodomains were shed, and if LRIG1 could regulate cell proliferation and EGF signaling in a paracrine manner. Cells constitutively shed LRIG1 ectodomains in vitro, and shedding was modulated by known regulators of metalloproteases, including the ADAM17 specific inhibitor TAPI-2. Furthermore, shedding was enhanced by ectopic expression of Adam17. LRIG1 ectodomains appeared to be shed in vivo, as well, as demonstrated by immunoblotting of mouse and human tissue lysates. Ectopic expression of LRIG1 in lymphocytes suppressed EGF signaling in co-cultured fibroblastoid cells, demonstrating that shed LRIG1 ectodomains can function in a paracrine fashion. Purified LRIG1 ectodomains suppressed EGF signaling without any apparent downregulation of EGFR levels. Taken together, the results show that the LRIG1 ectodomain can be proteolytically shed and can function as a non-cell-autonomous regulator of growth factor signaling. Thus, LRIG1 or its ectodomain could have therapeutic potential in the treatment of growth factor receptor-dependent cancers. Copyright Â
© 2010 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21087604     DOI: 10.1016/j.yexcr.2010.11.005

Source DB:  PubMed          Journal:  Exp Cell Res        ISSN: 0014-4827            Impact factor:   3.905


  23 in total

1.  MicroRNA-19a promotes glioma cell growth by repressing LRIG1.

Authors:  Ling-Min Shao; Ji-An Yang; Yue-Fei Wang; Peng Wu; Ji-Qiang Li; Qian-Xue Chen
Journal:  Int J Clin Exp Med       Date:  2014-12-15

Review 2.  The LRIG family: enigmatic regulators of growth factor receptor signaling.

Authors:  Catalina Simion; Maria Elvira Cedano-Prieto; Colleen Sweeney
Journal:  Endocr Relat Cancer       Date:  2014-09-02       Impact factor: 5.678

3.  Immunohistochemical analysis of LRIG proteins in meningiomas: correlation between estrogen receptor status and LRIG expression.

Authors:  Soma Ghasimi; Hannu Haapasalo; Mine Eray; Katariina Korhonen; Thomas Brännström; Håkan Hedman; Ulrika Andersson
Journal:  J Neurooncol       Date:  2012-04-08       Impact factor: 4.130

Review 4.  Feedback regulation of RTK signaling in development.

Authors:  Cynthia L Neben; Megan Lo; Natalia Jura; Ophir D Klein
Journal:  Dev Biol       Date:  2017-10-26       Impact factor: 3.582

5.  Leucine-rich repeat and immunoglobulin domain-containing protein-1 (Lrig1) negative regulatory action toward ErbB receptor tyrosine kinases is opposed by leucine-rich repeat and immunoglobulin domain-containing protein 3 (Lrig3).

Authors:  Hanine Rafidi; Francisco Mercado; Michael Astudillo; William H D Fry; Matthew Saldana; Kermit L Carraway; Colleen Sweeney
Journal:  J Biol Chem       Date:  2013-05-30       Impact factor: 5.157

6.  LRIG1 is a conserved EGFR regulator involved in melanoma development, survival and treatment resistance.

Authors:  Ola Billing; Ylva Holmgren; Daniel Nosek; Håkan Hedman; Oskar Hemmingsson
Journal:  Oncogene       Date:  2021-05-04       Impact factor: 9.867

Review 7.  LRIG1, a regulator of stem cell quiescence and a pleiotropic feedback tumor suppressor.

Authors:  Yibing Ji; Rahul Kumar; Abhiram Gokhale; Hseu-Ping Chao; Kiera Rycaj; Xin Chen; Qiuhui Li; Dean G Tang
Journal:  Semin Cancer Biol       Date:  2021-01-18       Impact factor: 17.012

8.  Gene expression pattern of the epidermal growth factor receptor family and LRIG1 in renal cell carcinoma.

Authors:  Marcus Thomasson; Håkan Hedman; Börje Ljungberg; Roger Henriksson
Journal:  BMC Res Notes       Date:  2012-05-03

9.  The soluble form of the tumor suppressor Lrig1 potently inhibits in vivo glioma growth irrespective of EGF receptor status.

Authors:  Mikael Johansson; Anaïs Oudin; Katja Tiemann; Amandine Bernard; Anna Golebiewska; Olivier Keunen; Fred Fack; Daniel Stieber; Baofeng Wang; Håkan Hedman; Simone P Niclou
Journal:  Neuro Oncol       Date:  2013-05-30       Impact factor: 12.300

Review 10.  LRIG1 is a triple threat: ERBB negative regulator, intestinal stem cell marker and tumour suppressor.

Authors:  Y Wang; E J Poulin; R J Coffey
Journal:  Br J Cancer       Date:  2013-04-04       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.